BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 22560635)

  • 1. Genetic protein TmSm(T34A) enhances sensitivity of chemotherapy to breast cancer cell lines as a synergistic drug to doxorubicin.
    Xu Y; Zheng W; Wang T; Wang P; Zhu L; Ma X
    Biomed Pharmacother; 2012 Jul; 66(5):368-72. PubMed ID: 22560635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A recombinant protein TmSm(T34A) can inhibit proliferation and proapoptosis to breast cancer stem cells(BCSCs) by down-regulating the expression of Cyclin D1.
    Ma X; Zhang Y; Kang Y; Li L; Zheng W
    Biomed Pharmacother; 2016 Dec; 84():373-381. PubMed ID: 27668537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-level expression, purification and pro-apoptosis activity of HIV-TAT-survivin (T34A) mutant to cancer cells in vitro.
    Ma X; Zheng W; Wei D; Ma Y; Wang T; Wang J; Liu Q; Yang S
    J Biotechnol; 2006 May; 123(3):367-78. PubMed ID: 16406157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.
    Keane MM; Ettenberg SA; Nau MM; Russell EK; Lipkowitz S
    Cancer Res; 1999 Feb; 59(3):734-41. PubMed ID: 9973225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic antitumoral effect of combination E gene therapy and Doxorubicin in MCF-7 breast cancer cells.
    Rama AR; Prados J; Melguizo C; Burgos M; Alvarez PJ; Rodriguez-Serrano F; Ramos JL; Aranega A
    Biomed Pharmacother; 2011 Jul; 65(4):260-70. PubMed ID: 21723082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
    Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
    Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.
    Shuhendler AJ; Cheung RY; Manias J; Connor A; Rauth AM; Wu XY
    Breast Cancer Res Treat; 2010 Jan; 119(2):255-69. PubMed ID: 19221875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preparation of recombinant HIV-TATm-survivin (T34A) protein and its pro-apoptosis activity to cancer cells in vitro].
    Zheng WY; Ma XY; Wei DZ; Wang JZ; Liu QH; Ma YS; Yang SL
    Sheng Wu Gong Cheng Xue Bao; 2006 Mar; 22(2):285-92. PubMed ID: 16607958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer.
    Kawasaki K; Watanabe M; Sakaguchi M; Ogasawara Y; Ochiai K; Nasu Y; Doihara H; Kashiwakura Y; Huh NH; Kumon H; Date H
    Cancer Gene Ther; 2009 Jan; 16(1):65-72. PubMed ID: 18654608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
    Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
    Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multidrug resistance-1 (MDR-1) system.
    Günthert AR; Gründker C; Bongertz T; Nagy A; Schally AV; Emons G
    Breast Cancer Res Treat; 2004 Oct; 87(3):255-64. PubMed ID: 15528968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oestrogen treatment enhances the sensitivity of hormone-resistant breast cancer cells to doxorubicin.
    Scherbakov AM; Lobanova YS; Andreeva OE; Shatskaya VA; Krasil'nikov MA
    Biosci Rep; 2011 Apr; 31(2):137-43. PubMed ID: 20662767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin.
    Abu Ajaj K; Graeser R; Kratz F
    Breast Cancer Res Treat; 2012 Jul; 134(1):117-29. PubMed ID: 22228402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction, expression, and purification of HIV-TAT-survivin (T34A) mutant: a pro-apoptosis protein in Escherichia coli.
    Ma X; Zheng W; Wei D; Ma Y; Wang T; Wang J; Liu Q; Yang S
    Protein Expr Purif; 2006 May; 47(1):36-44. PubMed ID: 16260148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of human breast carcinoma MCF-7 cells differing in their resistance to doxorubicin: effect of ionizing radiation on apoptosis and TGF-beta production.
    Chorna I; Bilyy R; Datsyuk L; Stoika R
    Exp Oncol; 2004 Jun; 26(2):111-7. PubMed ID: 15273662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug resistance in chemotherapy for breast cancer.
    Saeki T; Tsuruo T; Sato W; Nishikawsa K
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptosis repressor with caspase recruitment domain contributes to chemotherapy resistance by abolishing mitochondrial fission mediated by dynamin-related protein-1.
    Wang JX; Li Q; Li PF
    Cancer Res; 2009 Jan; 69(2):492-500. PubMed ID: 19147562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
    Harris LN; Yang L; Tang C; Yang D; Lupu R
    Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
    Györffy B; Serra V; Jürchott K; Abdul-Ghani R; Garber M; Stein U; Petersen I; Lage H; Dietel M; Schäfer R
    Oncogene; 2005 Nov; 24(51):7542-51. PubMed ID: 16044152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The differential sensitivity of Bc1-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bc1-2 protein levels.
    Ruiz de Almodóvar C; Ruiz-Ruiz C; Muñoz-Pinedo C; Robledo G; López-Rivas A
    Oncogene; 2001 Oct; 20(48):7128-33. PubMed ID: 11704839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.